NEW YORK, June 30, 2016 /PRNewswire/ --
Lagging the market yesterday was the Biotech space, which
continues to be challenged by costs, economic uncertainty, and
policies. Stock-Callers.com reviews the recent performances of the
following equities today: ImmunoGen Inc. (NASDAQ: IMGN),
Immunomedics Inc. (NASDAQ: IMMU), Vanda Pharmaceuticals Inc.
(NASDAQ: VNDA), and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR).
Sign up for your complimentary trade alerts on these stocks at:
http://stock-callers.com/registration
To access Stock-Callers.com full PDF Research
Packages for free, please visit the links below.
============
Full PDF DOWNLOAD Links
(You may have to copy and paste the links into your browser)
IMGN Research
Package: http://stock-callers.com/registration/?symbol=IMGN
IMMU Research
Package: http://stock-callers.com/registration/?symbol=IMMU
VNDA Research
Package: http://stock-callers.com/registration/?symbol=VNDA
ARWR Research
Package: http://stock-callers.com/registration/?symbol=ARWR
============
Waltham, Massachusetts
headquartered biotechnology Company ImmunoGen Inc.'s stock finished
Wednesday's session at $3.13, which
was a decline of 1.57%. A total volume of 2.03 million shares was
traded. The Company's shares are trading 45.02% below their 50-day
moving average. Additionally, shares of ImmunoGen, which develops
targeted anticancer therapeutics, have a Relative Strength Index
(RSI) of 22.92.
On Wednesday, shares in Morris Plains,
New Jersey headquartered clinical-stage biopharmaceutical
Company, Immunomedics Inc., recorded a trading volume of 2.35
million shares, which was above their three months average volume
of 2.26 million shares. The stock ended the session 3.21% higher at
$2.25. The Company's shares are
trading 18.26% below their 200-day moving average. Moreover, shares
of Immunomedics, which focuses on the development of monoclonal
antibody-based products for the targeted treatment of cancer,
autoimmune, and other diseases, have an RSI of 32.47.
Shares in Washington, the
District of Columbia headquartered
biopharmaceutical Company, Vanda Pharmaceuticals Inc., closed the
day 0.63% lower at $11.11. The stock
recorded a trading volume of 430,227 shares. The Company's shares
have gained 6.83% in the last month, 32.89% in the previous three
months, and 19.33% on an YTD basis. The stock is trading 12.44%
above its 50-day moving average and 16.60% above its 200-day moving
average. Additionally, shares of Vanda Pharmaceuticals, which
focuses on the development and commercialization of products for
the treatment of central nervous system disorders, have an RSI of
57.77.
At the close, shares in Pasadena,
California headquartered biopharmaceutical Company,
Arrowhead Pharmaceuticals Inc., ended the day at $5.41, gaining 1.88%. The stock recorded a
trading volume of 351,782 shares. The Company's shares have
advanced 12.24% in the previous three months. The stock is trading
above its 200-day moving average by 1.70%. Furthermore, shares of
Arrowhead Pharmaceuticals, which develops novel drugs to treat
intractable diseases in the U. S., have an RSI of 41.64.
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored
reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and
micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
SC has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer") represented by a
credentialed financial analyst [for further information on analyst
credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and
reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author
according to the procedures outlined by SC. SC is not entitled to
veto or interfere in the application of such procedures by the
third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content
outside of this document has no association with the Author or the
Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any
error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is
accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the
Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither SC nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly.
If you're a company we are
covering and wish to no longer feature on our coverage list contact
us via email and/or phone between 09:30 EDT
to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street,
Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Chelmsford Park SA